6 research outputs found
Production of Medical Radioisotopes with High Specific Activity in Photonuclear Reactions with Beams of High Intensity and Large Brilliance
We study the production of radioisotopes for nuclear medicine in
photonuclear reactions or ()
photoexcitation reactions with high flux [()/s], small
diameter m and small band width () beams produced by Compton back-scattering of laser
light from relativistic brilliant electron beams. We compare them to (ion,np) reactions with (ion=p,d,) from particle accelerators like
cyclotrons and (n,) or (n,f) reactions from nuclear reactors. For
photonuclear reactions with a narrow beam the energy deposition in the
target can be managed by using a stack of thin target foils or wires, hence
avoiding direct stopping of the Compton and pair electrons (positrons).
isomer production via specially selected cascades
allows to produce high specific activity in multiple excitations, where no
back-pumping of the isomer to the ground state occurs. We discuss in detail
many specific radioisotopes for diagnostics and therapy applications.
Photonuclear reactions with beams allow to produce certain
radioisotopes, e.g. Sc, Ti, Cu, Pd, Sn,
Er, Pt or Ac, with higher specific activity and/or
more economically than with classical methods. This will open the way for
completely new clinical applications of radioisotopes. For example Pt
could be used to verify the patient's response to chemotherapy with platinum
compounds before a complete treatment is performed. Also innovative isotopes
like Sc, Cu and Ac could be produced for the first time
in sufficient quantities for large-scale application in targeted radionuclide
therapy.Comment: submitted to Appl. Phys.
Current state of quality of life and patient-reported outcomes research
The 5th EORTC Quality of Life in Cancer Clinical Trials Conference presented the current state of quality of life and other patient-reported outcomes (PROs) research from the perspectives of researchers, regulators, industry representatives, patients and patient advocates and health care professionals. A major theme was the assessment of the burden of cancer treatments, and this was discussed in terms of regulatory challenges in using PRO assessments in clinical trials, patients' experiences in cancer clinical trials, innovative methods and standardisation in cancer research, innovative methods across the disease sites or populations and cancer survivorship. Conferees demonstrated that PROs are becoming more accepted and major efforts are ongoing internationally to standardise PROs measurement, analysis and reporting in trials. Regulators are keen to collaborate with all stakeholders to ensure that the right questions are asked and the right answers are communicated. Improved technology and increased flexibility of measurement instruments are making PROs data more robust. Patients are being encouraged to be patient partners. International collaborations are essential, because this work cannot be accomplished on a national level
Cytotoxicity of PAI2, C595 and Herceptin Vectors Labeled with the Alpha-Emitting Radioisotope Bismuth-213 for Ovarian Cancer Cell Monolayers and Clusters
The vectors PAI2, C595 and Herceptin target the membrane-bound uPA, MUCl and HER2 antigens expressed by cancer cells, respectively. The expression of these receptors was tested in the ovarian cancer cell line OVCAR-3; MUC-I was strongly expressed (3 -|->, uPA moderately expressed (2+), but HER2 was negatíveJRC.E.5-Nuclear chemistr
MUC1 Expression in Primary and Metastatic Pancreatic Cancer Cells for in vitro Treatment by 213Bi-C595 Radioimmunoconjugate
Abstract not availableJRC.E-Institute for Transuranium Elements (Karlsruhe